Understanding Comorbidities in RMD People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f

#OP0159 #EULAR2026 Multimodal study in D2T RA identified altered brain connectivity patterns linked to pain, psychological features & peripheral transcriptomics. Supports neuroimmune component in D2T RA & need for personalised approaches beyond inflammation control. @RheumNow https://t.co/qMQbkiMCwX

• https://x.com/DrMiniDey/status/2063190408264339597/photo/1

Does #RA accelerate age-related functional decline in older adults? STAR study (n=421, age 55-85): RA with worse HAQ, grip strength, but aging's effect on function similar in RA vs controls. Geriatric syndromes like sarcopenia may matter more than RA @RheumNow #EULAR2026 POS0360

Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs? RISE registry Retrospective N=60,206 Tirzepatide: lost 8% Semaglutide: list 6% At 12 months PsA had the highest usage OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr

• https://x.com/Nellziade/status/2063257930455990410/photo/1

Machine learning identifies a “vulnerable” phenotype in older RA patients n=275 -51% “vulnerable” -Worse grip strength, gait speed & SARC-F -Higher disability (HAQ 1.56 vs 0.64) -More fatigue, poorer QoL -Higher DAS28 despite greater biologic exposure Suggests we should assess https://t.co/bv1FbTxGKR

• https://x.com/AurelieRheumo/status/2063143217885855817/photo/1

Failure to achieve early remission RA asso w/ non-inflammatory pain NORD-STAR 526 early RA pts) no remission at 24 wks increased risk of 48wk • unacceptable pain (OR ~6) • refractory pain (OR ~6) • fibromyalgic RA (OR ~16) Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw

• https://x.com/AurelieRheumo/status/2062950853187695084/photo/1

What does remission really mean to patients with #PsA? The RemiPPsA international qualitative study asked 123 patients across 11 countries. Pain-free + ability to resume daily life topped the list, not just composite scores. #EULAR2026 @RheumNow, POS0294 https://t.co/mEGpkewuTX

• https://x.com/JihaRheum/status/2062888670106161256/photo/1

What does remission look like for people living with PsA? Much more than the absence of swollen joints Absence of pain Skin management Ability to resume daily activities Sustained over time A definition not always reflected in our disease activity scores #POS0294 #EULAR2026 https://t.co/VCnMGAOVYm

• https://x.com/AurelieRheumo/status/2062840184509468983/photo/1
• https://x.com/AurelieRheumo/status/2062840184509468983/photo/1

PET-derived parameters in #PsA correlated with DAPSA, CRP and patient pain. Angiogenesis imaging may be a complementary biomarker of overall disease burden Abstr#OP068 #EULAR2026 #Imaging

#EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN

• https://x.com/Yuz6Yusof/status/2062442028848296425/photo/1

🔮 Can polygenic risk scores predict PsA timing in psoriasis? Another GWAS study (n=703) says YES! 70-SNP model achieves AUC 0.843 for predicting PsA onset <10 vs >10 years #POS0088 #EULAR2026 @RheumNow https://t.co/wI4Jy8Yu2A

• https://x.com/Nellziade/status/2062593920366731584/photo/1

@RheumNow HOT #Obesity session (7) 📢A call for action Current RMD treatments ignore obesity: They all target immune response but miss the metabolic-inflammatory loop Breaking that cycle may be the missing piece Obesity must be part of every rheumatology plan #EULAR2026 @rheumnow

Treatment for #lupus #brain #fog?! #small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #Alzheimers SLE-more permeability in #brain #SLE -antiDNA cross reacting w NDAR #memantine N=19 v #PBO N=25 showed more improvemt #EULAR2026 @RheumNow POS701 https://t.co/qvHOy9oDS7

• https://x.com/Janetbirdope/status/2062540663443362243/photo/1

ClearMEMory: Ph2 RCT evaluating memantine for tx of cognitive impairment in SLE using RBANS as outcome measure MEM grp had sig. higher change in RBANS TIScore upto wk 12 vs. PBO, esp. immediate memory index score Potential adjunct tx for NPSLE? AbsPOS0701 @RheumNow #EULAR2026 https://t.co/UffdVPRu6s

• https://x.com/RHEUMarampa/status/2062506356192538724/photo/1